Suppliers / Kindeva Drug Delivery

Kindeva Drug Delivery

United Kingdom Updated 9 July 2026

Kindeva Drug Delivery is a finished-dose manufacturer based in United Kingdom. It appears in 9 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with NPRA (MY), EDE (AE) and ARCSA (EC). Its GMP standing is certified by MHRA (UK), MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 14 March 2025 as VAI.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
9
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 14 March 2025 VAI US FDA
  • 27 May 2021 VAI US FDA
  • 3 May 2018 VAI US FDA
  • 30 June 2017 VAI US FDA
  • 12 August 2016 VAI US FDA
  • 5 March 2015 NAI US FDA
  • 15 April 2013 VAI US FDA
  • 17 April 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Loughborough, United Arab Emirates Not on file
LOUGHBOROUGH, United Kingdom Not on file
United Kingdom, United Kingdom 3002807586

Filings and GMP by regulator

Regulator Filings GMP certificates
NPRA (MY) 6 None
EDE (AE) 2 None
ARCSA (EC) 1 None
MHRA (UK) None 7
MFDS (Korea) None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Kindeva Drug Delivery comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 14 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates